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Abstract
Background:  Hereditary hemochromatosis (HH) is a common inherited disorder of iron
metabolism in Northern European populations. The discovery of a candidate gene in 1996 (HFE),
and of its main mutation (C282Y), has radically altered the way to diagnose this disease. The aim
of this study was to assess the impact of the HFE gene discovery on the clinical presentation and
epidemiology of HH.
Methods: We studied our cohort of 415 patients homozygous for the C282Y allele and included
in a phlebotomy program in a blood centre in western Brittany, France.
Results: In this cohort, 56.9% of the patients were male and 21.9% began their phlebotomy
program before the implementation of the genetic test. A significant decrease in the sex ratio was
noticed following implementation of this DNA test, from 3.79 to 1.03 (p < 10-5), meaning that the
proportion of diagnosed females relatives to males greatly increased. The profile of HH patients at
diagnosis changed after the DNA test became available. Serum ferritin and iron values were lower
and there was a reduced frequency of clinical signs displayed at diagnosis, particularly skin
pigmentation (20.1 vs. 40.4%, OR = 0.37, p < 0.001) and hepatomegaly (11.0 vs. 22.7%, OR = 0.42,
p = 0.006). In contrast, fatigue became a more common symptom at diagnosis (68.0 vs. 51.2%, OR
= 2.03, p = 0.004).
Conclusion: This study highlights the importance of the HFE gene discovery, which has simplified
the diagnosis of HH and modified its clinical presentation and epidemiology. This study precisely
measures these changes. Enhanced diagnosis of HFE-related HH at an early stage and
implementation of phlebotomy treatment are anticipated to maintain normal life expectancy for
these patients.
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Background
Hereditary hemochromatosis (HH) is a common genetic
disorder of iron metabolism that is usually inherited in an
autosomal recessive pattern and associated with missense
mutations in the HFE  gene. This pathology displays a
large genetic heterogeneity because several other types of
hemochromatosis, associated with different genes and
patterns of inheritance, have been reported [1]: HH type
2B is a juvenile form linked to the HAMP gene (encoding
for hepcidin) [2-4], HH type 3 is linked to the TfR2 gene
(encoding for transferrin receptor 2) [5-7], HH type 4 is
linked to the SLC11A3 gene (encoding for ferroportin, an
intestinal iron transporter) [8,9]. and HH type 5 is linked
to a gene encoding subunit H of ferritin [10]. Moreover,
the gene responsible for juvenile hemochromatosis (HH
type 2A), and whose protein product is called hemojuve-
lin, has recently been cloned [11].
The main form of HH (i.e. type I which is linked to the
HFE gene) occurs predominantly in Northern European
populations, with a prevalence of approximately 3 to 8 in
1000 [12-16]. It is characterised by excessive iron absorp-
tion, which progressively leads to the destruction of tis-
sues in different organs of the body. After a phase of
latency, the first signs of biochemical expression appear,
generally around the age of 20. This is characterised by
increases in serum iron parameters (transferrin saturation,
ferritin). The clinical expression manifests later during
adulthood, generally around the age of 40 in males and
later in females, around the age of 50, because of the pro-
tective effects of menstrual blood loss and pregnancies
[17-19]. The clinical picture may include at an early stage,
non-specific symptoms such as persistent fatigue and
arthralgias, and at a later stage, clinical signs such as skin
pigmentation, hepatomegaly, arthropathy, cardiomyopa-
thy, diabetes and cirrhosis [20-22]. Classically, this clini-
cal expression occurs more frequently in males than in
females (sex ratio of 3:1) [23].
HH can be treated or prevented by periodic phlebotomies.
This simple and efficient treatment prevents iron accumu-
lation and clinical complications. Without this early treat-
ment, the disease may progress towards irreversible
damage such as cirrhosis and hepatocellular carcinoma
[17-19].
A candidate gene for HH type 1, HFE, was identified in
1996 on chromosome 6 and encodes the HFE protein, a
transmembrane glycoprotein that is implicated in modu-
lation of iron uptake [24,25]. Currently, about twenty dif-
ferent mutations have been identified in this gene
worldwide and, one of them, termed C282Y, is present at
homozygous state in 80 to 95% of HH patients. This
molecular anomaly corresponds to the substitution of a
tyrosine for a cysteine at amino acid 282, which prevents
formation of a disulfide bond [24,26]. The two other most
common mutations of the HFE gene are associated with
milder forms of HH (H63D and S65C) [1,21,27-29].
The discovery of the HFE gene in 1996 and the fact that
one of its mutations (C282Y) is responsible for the large
majority of HH cases enabled the implementation of effi-
cient strategies for molecular diagnosis [30], what has
altered the way in which HH is diagnosed. Initially, the
diagnosis relied on a high index of suspicion associated
with evidence of elevated iron parameter values
[18,20,22]. Following discovery of the HFE gene, a DNA
test was proposed to confirm the diagnosis of HH. Such a
test, which allows the detection of at least the C282Y
mutation, is now widely available. This discovery has sim-
plified the diagnostic strategy and enabled pre-sympto-
matic or earlier diagnosis in some patients. If phlebotomy
treatment is implemented before the appearance of irre-
versible damage, the excess iron can be removed and
patients have a normal life expectancy [20,31].
In this study, we assessed the impact of HFE genetic test-
ing on the clinical presentation and epidemiology of HH
in a cohort of 415 patients homozygous for the C282Y
mutation who were followed in a blood centre in western
Brittany, France. This report contains objective data to
measure this impact.
Methods
Study population
The present study was conducted in Brittany, a region of
nearly three million inhabitants located in the north-west-
ern part of France, where HH is particularly frequent (car-
rier rate: 1 in 7) [32]. This disease presents a large genetic
and allelic heterogeneity, but as the majority of patients
are homozygous for the C282Y mutation, we decided to
include in this study only the patients homozygous for
this mutation. This study included all the C282Y
homozygous patients who are or were included in a phle-
botomy program in a blood centre of western Brittany and
who presented with transferrin saturations of greater than
or equal to 45%. The first patients began their treatment
in the early eighties and the last date of patient entry for
inclusion in this study was December 31st 2003. The pro-
portion of homozygous C282Y patients before and after
the implementation of the genetic test did not change
significantly.
Clinical questionnaire
A detailed clinical questionnaire was completed during
the clinical exam performed at the first visit of patients to
the blood centre (i.e. at entry in the phlebotomy pro-
gram). Information contained in this questionnaire was
previously described in detail [33]. Briefly, it provided
information regarding socio-demographic characteristicsBMC Medical Genetics 2005, 6:24 http://www.biomedcentral.com/1471-2350/6/24
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of patients, their age at diagnosis, the circumstances of
HH discovery, the biochemical parameters and the clini-
cal signs associated at the time of diagnosis. This question-
naire also included data related to the treatment, such as
the number and quantity of phlebotomies needed to
reach depletion and the quantity of iron extracted. The
date of the beginning of the treatment (i.e. entry into the
phlebotomy program) was also documented. This date
was used to determine if the treatment of patients began
before or after the availability of the genetic test (i.e.
1996). The intake of alcohol was assessed by a detailed
item included in the questionnaire, which measured the
number of glasses of alcohol drunk each day (including
glasses of wine, beer and liquor). These data enabled the
quantity of ethanol (in grams) consumed each day, by
each patient of the cohort, to be determined. Excessive
alcohol consumption was defined as a daily consumption
greater than or equal to 60 grams of ethanol [33].
Determination of biochemical parameter levels and of 
HFE genotype
Serum iron parameters (i.e. serum iron, serum ferritin and
serum transferrin saturation) were determined by stand-
ard biochemical methods (including collection of serum
after a 12-hour fast, confirmation by at least two
measurements).
Analysis of the C282Y mutation relies on amplification of
the specific gene region by the polymerase chain reaction,
followed by mutation detection using restriction enzymes
[29,32]. Recently, another method was adopted for this
analysis: the denaturing high-performance liquid chroma-
tography method [34]. If the DNA test confirms the pres-
ence of mutations in a patient, family testing is offered to
the relatives of this newly diagnosed patient. Family test-
ing combines the collection of biochemical and clinical
evidence of iron overload for the patients relatives with
analysis of the main HFE mutations. Before 1996, family
testing was already possible by analysis of HLA haplotypes
in families [35] and this was commonly practised in our
region where the disease incidence is high. The genotype
of the patients diagnosed before 1996 was retrospectively
determined when the genetic test became available.
Statistical analysis
Data were analysed using Epi-Info software (version 6.04;
Centers for Disease Control and Prevention, Atlanta,
Georgia) and SAS statistical package (version 8.2; SAS
Institute). Quantitative variables, expressed as means and
standard deviations, were compared with the Student's t
test or ANOVA, whereas qualitative variables, expressed as
percentages, were compared with the Chi square test or
the Fisher's exact test (in case of small sample size). A log-
arithmic transformation was performed for the serum fer-
ritin variable which had a skewed distribution. A
significance level of 5% was used for all of the analyses
which were performed two-sided.
The analyses consisted of determining the influence of the
implementation of the genetic test on the sex ratio, the age
at diagnosis, the circumstances of HH discovery, the levels
of biochemical parameters and the frequency of clinical
signs associated at the time of diagnosis. The comparisons
of biochemical and clinical data, which were made sepa-
rately for males and females, were adjusted for age at diag-
nosis and for alcohol consumption, because we showed
previously that excessive alcohol consumption (>60 g/
day) increased HH expressivity [33]. The relation between
the time of diagnosis (i.e. before or after availability of
HFE genotyping) and each of the different clinical symp-
toms was assessed by calculating the odds-ratio (OR) and
its 95% confidence interval (CI).
This study complied with French bioethical regulations.
Informed consent of patients was obtained before blood
samples were taken.
Results
Description of the study population
This study included 415 C282Y homozygous patients of
whom 56.9% were male, resulting in a sex ratio of 1.3:1
(236/179). The age at diagnosis, ranging from 13 to 76
years, was significantly higher in females than in males
Evolution of the sex ratio: number of males and females diag- nosed before and after the implementation of the genetic  test Figure 1
Evolution of the sex ratio: number of males and females diag-
nosed before and after the implementation of the genetic 
test.
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(48.5 yrs (σ  = 14.3) vs. 46.1 yrs (σ  = 12.5), p = 0.037).
Overall, the diagnosis was mainly made on the basis of
clinical features (61.4%) or through family testing
(30.9%). The circumstances of diagnosis remained
unknown for one patient. Among these 415 patients,
21.9% began their phlebotomy program before the
implementation of the molecular testing (n = 91, 72
males and 19 females) and 78.1% after this date (n = 324,
164 males and 160 females).
Characteristics of patients before and after the 
implementation of the genetic test
Socio-demographic characteristics of patients in relation to the type 
of diagnosis (based on HFE genotyping or not)
A significant decrease in the sex ratio was noted following
development of the genetic test, as illustrated in figure 1.
The sex ratio was 3.79 (72/19) before discovery of the
gene and 1.03 (164/160) after this date (p < 10-5), mean-
ing that the proportion of females diagnosed since 1996
increased greatly: from 20.9% (19/91) to 49.4% (160/
324). These females seemed to be diagnosed earlier. Their
age at diagnosis tended to decrease from 52.9 yrs (σ  = 9.8)
before the implementation of the genetic test to 47.9 yrs
(σ  = 14.7) after this date. Nevertheless, this difference was
not significant because a small number of women was
diagnosed before 1996 (n = 19, p = 0.210). This pattern
was not observed in males, their age at diagnosis increased
from 42.7 yrs (σ  = 10.4) to 47.6 yrs (σ  = 13.1) after 1996
(p = 0.007).
After introduction of molecular testing, the symptom of
unexplained and persistent fatigue was more commonly
present at diagnosis of HH. The frequency of this symp-
tom increased from 51.2 to 68.0% following introduction
of the DNA-based testing (OR = 2.03, 95% CI: 1.21, 3.41;
p = 0.004), notably in males (from 47.1 to 58.4%). On
the other hand, the proportion of patients detected by
family testing was not significantly changed after 1996
(31.3 vs. 29.7%).
Biochemical parameters in relation to the type of diagnosis (based on 
HFE genotyping or not)
Differences were also observed in biochemical parameter
values. The results of the comparison of the biochemical
data of patients before and after the development of the
genetic test are presented in table 1. Serum ferritin and
serum iron values were significantly lower in patients
diagnosed after implementation of the genetic test (serum
ferritin: 810.4 vs. 1788.8 µg/liter, p < 0.001; serum iron:
34.9 vs. 39.8 µmol/liter, p < 0.001). These results were
observed in males (serum ferritin: 1136.9 vs. 1886.6 µg/
liter, p < 0.001; serum iron: 36.7 vs. 40.7 µmol/liter, p <
0.001) and in females (serum ferritin: 475.7 vs. 1418.0
µg/liter, p < 0.001; serum iron: 33.1 vs. 36.6 µmol/liter, p
= 0.052). As shown in table 1, the results remained
unchanged after adjustment for age at diagnosis and alco-
hol consumption. In this cohort, 8.0% of the patients
declared having excessive alcohol consumption (≥  60 g/
day; n = 33) comprising 9.9% of the patients diagnosed
before 1996 (n = 9) and 7.4% of those diagnosed after
1996 (n = 24). A decrease was not observed for the third
iron parameter, transferrin saturation (79.5 vs. 79.4%, p =
0.930), for which an elevated value (>45%) was used as a
selection criterion for this study.
Table 1: Biochemical characteristics of the C282Y homozygous patients before and after the implementation of the genetic test.
Diagnosis based on HFE genotyping Crude p-value Adjusted* p-value
No Yes
mean (SD) mean (SD)
No. of patients 91 324
Gender (no. and % of males) 72 (79.1%) 164 (50.6%) p < 10-5 -
Males
Serum ferritin (µg/L) 1886.6 (1769.7) 1136.9 (951.0) <0.001 <0.001
Serum iron (µmol/L) 40.7 (6.9) 36.7 (6.7) <0.001 <0.001
Transferrin saturation (%) 79.9 (11.9) 83.0 (13.2) 0.090 0.134
Females
Serum ferritin (µg/L) 1418.0 (1457.9) 475.7 (744.6) <0.001 <0.001
Serum iron (µmol/L) 36.6 (8.2) 33.1 (7.4) 0.052 0.029
Transferrin saturation (%) 77.2 (13.4) 75.9 (14.4) 0.710 0.714
* Adjusted for age at diagnosis and alcohol consumptionBMC Medical Genetics 2005, 6:24 http://www.biomedcentral.com/1471-2350/6/24
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Frequency of the main clinical signs and symptoms at the time of diagnosis in males, before and after the implementation of the  genetic test Figure 2
(A) Frequency of the main clinical signs and symptoms at the time of diagnosis in males, before and after the implementation of 
the genetic test. (B) Frequency of the main clinical signs and symptoms at the time of diagnosis in females, before and after the 
implementation of the genetic test
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Clinical signs in relation to type of diagnosis (based on HFE 
genotyping or not)
The frequency of the main clinical signs observed at the
time of diagnosis before and after the availability of the
molecular testing is shown in figures 2A and 2B. The clin-
ical signs were less frequent in the subjects diagnosed after
the development of the genetic test, particularly skin pig-
mentation (20.1 vs. 40.4%; OR = 0.37, 95% CI = 0.22,
0.63; p < 0.001) and hepatomegaly (11.0 vs. 22.7%; OR =
0.42, 95% CI = 0.21, 0.83; p = 0.006). This change was
more significant in women. Indeed, only the two signs
mentioned above tended to be less frequently observed in
men following the introduction of genetic testing
although these changes did not reached statistical signifi-
cance (skin pigmentation: 32.1 vs. 43.7%; OR = 0.61,
95% CI = 0.33, 1.13; p = 0.089 – hepatomegaly: 14.7 vs.
22.5%; OR = 0.59, 95% CI = 0.27, 1.32; p = 0.160),
whereas in women, four symptoms were significantly less
frequent following implementation of molecular testing:
skin pigmentation (7.6 vs. 27.8%; OR = 0.22, 95% CI =
0.06, 0.84; p = 0.006), hepatomegaly (7.3 vs. 23.5%; OR
= 0.26, 95% CI = 0.06, 0.86; p = 0.028), arthritis (47.5 vs.
76.5%; OR = 0.28, 95% CI = 0.07, 0.98; p = 0.023) and
diabetes (2.0 vs. 16.7%; OR = 0.10, 95% CI = 0.01, 0.71;
p = 0.001). These results were similar in the sub-group of
patients having no excessive alcohol consumption (data
not shown).
Discussion
The discovery of the HFE gene in 1996 constituted a con-
siderable advance in the medical and scientific field. This
discovery concerned one of the most common inherited
disorders in white populations, HH – a disorder that was
complex to diagnose but for which a treatment existed –
and identified one of the few undiscovered genes that has
an important impact on public health.
The symptomatology of HH has evolved over the past
years and it is now rare to diagnose severe forms of the dis-
ease, associated with diabetes, cirrhosis and darkened skin
[36,37]. Through a survival analysis based on a cohort of
251 patients diagnosed between 1947 and 1991, Nied-
erau et al. showed that the percentage of patients with
early diagnoses increased 3-fold during the period of
1970–1981 compared to the period of 1947–1969, and
that there was a further 20–25% increase in the early diag-
nosis rate during the period of 1981–1991 [37]. These
changes occurred before the discovery of the HFE gene,
and were probably the consequences of improved educa-
tion of physicians and the implementation of HLA testing
for family members of probands.
The current study highlights the importance of the discov-
ery of the HFE gene in 1996 and demonstrates how the
clinical presentation and epidemiology of HH have
changed since the availability of the DNA test. Our results
objectively measure these changes, and show that the sex
ratio of this disease has altered: the proportion of females
currently diagnosed has increased and has reached that of
males. This study also highlights that the profile of HH
patients has changed: the patients have lower iron param-
eter values (serum ferritin and iron) and a lower frequency
of clinical signs at the time of diagnosis, notably skin pig-
mentation and hepatomegaly. This change is more pro-
nounced in females in whom clinical manifestations of
HH appears later than in males (around the age of 50 ver-
sus around the age of 40 in males). This study included all
the C282Y homozygous patients who are or were
included in a phlebotomy program in a blood centre of
western Brittany. For the patients diagnosed before the
implementation of the genetic test, the genotype was ret-
rospectively determined in 1996 if they were still alive at
this date. Consequently, the patients who died before
1996 were not genotyped and not included in this study.
With this bias, some severe cases of the disease have been
missed and the difference between the two groups should
therefore be even greater than reported here.
Identification of the HFE gene and of its main mutation
(C282Y) has greatly simplified diagnosis of, and family
testing for, HH [20,31]. The fact that homozygosity for the
C282Y mutation is responsible for the majority of HH
cases has enabled use of the molecular test for this muta-
tion as a diagnostic criterion for HH. Before the genetic
test was available, diagnosis of HH required a high index
of suspicion (as the clinical signs are non-specific) and
evidence of elevated iron parameters [18,20,22]. Tradi-
tionally, diagnosis was based on the measurement of
transferrin saturation. A liver biopsy then enabled
confirmation of iron overload by detection of elevated
hepatic iron levels [27]. The discovery of the HFE gene
enabled molecular analysis to be included in the diagnos-
tic strategy and thus genetic testing for confirmation of the
diagnosis was proposed. In this way, HH could easily be
differentiated from all other types of iron overload. Cur-
rently, the diagnosis combines molecular testing with tra-
ditional biochemical methods. The diagnostic strategy is
as follows: 1) To suspect the diagnosis from non-specific
symptoms (such as persistent fatigue, arthralgias), and
not only when presented with classical signs of HH (such
as skin pigmentation, diabetes and cirrhosis); 2) Once the
disease is suspected, the second step is to determine the
serum transferrin saturation; 3) If the value of this iron
parameter is elevated, molecular analysis of the main HFE
mutations (C282Y +/- H63D) must be done to confirm
the diagnosis of HH [20]. The diagnostic strategy has
changed, and as a consequence, patients with increased
iron parameter values and a genotype of HH are now diag-
nosed as having HH. The molecular basis of the disease
has been evidenced and inclusion of genetics in theBMC Medical Genetics 2005, 6:24 http://www.biomedcentral.com/1471-2350/6/24
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diagnostic strategy has enabled detection of iron overload
that is expressed only at a biochemical level.
The HFE gene discovery has improved our knowledge of
this complex disease. It has enabled the genotypes of
patients to be determined, and by considering this infor-
mation in relation to other factors such as age, gender and
environment, elucidation of genotype/phenotype correla-
tions has begun [33,38,39]. The HFE gene discovery also
raised the complex issue of the penetrance, which is
clearly incomplete [22,40-44]. It is probable that some of
the patients who exhibit biochemical evidence of iron
overload and a genotype of HH would never progress
towards the clinical manifestations of HH. Two studies
reported that less than 1% of the C282Y homozygous
subjects develops clinical hemochromatosis [40,45].
Unfortunately, studies on penetrance generally suffer
from bias that results in under or over-estimation of the
frequency of the disease [22,46]. Until more data are
available on the penetrance of the C282Y homozygous
state, screening using HFE genotyping remains controver-
sial [27,47].
Nevertheless, looking beyond this complex issue of pene-
trance, the gene discovery has led to a better understand-
ing of some of the phenotypic variability observed in HH.
This improved knowledge has been conducive to better
medical education of physicians, such that they now may
more often suspect a diagnosis of HH when presented
with non-specific symptoms (such as unexplained and
persistent fatigue) than they did previously. This educa-
tion is certainly not perfect at this time but we can observe
in the present study that the proportion of patients, partic-
ularly males, diagnosed with the symptom of fatigue has
already increased since the availability of HFE genotyping.
With astute clinical assessment and HFE genetic testing,
patients can be diagnosed and treated before the appear-
ance of irreversible damage, and this therefore avoids
development of severe forms of HH. In our study, an
increase in the age at diagnosis after the introduction of
the DNA test was observed in men. This could be
explained by the fact that a diagnosis of HH has been
done in some men older than 65 presenting with fatigue,
arthralgia and a discrete ferritin elevation. Those C282Y
homozygous patients would probably never have been
diagnosed ten years ago. The inclusion of these old diag-
nosed C282Y homozygous men in our cohort
significantly increased the age at diagnosis of HH during
the last years.
Family testing performed among the relatives of a newly
diagnosed patient also enables detection of subjects in the
pre-symptomatic phase. The discovery of the HFE gene
has not significantly altered family testing for HH
because, prior to 1996 it was already possible to analyze
the transmission of HLA haplotypes in families (the HFE
gene is located near the HLA complex). Such testing was
commonly practiced in our region where HH is common.
In our study, the proportion of patients detected by family
testing before and after the introduction of HFE genotyp-
ing was similar (29.7% versus 31.3%). Consequently, the
inclusion, in the present study, of patients identified
through family testing did not alter our findings. The
impact of the HFE gene test on the identification of HH
through family testing is expected to be higher in other
regions where family testing was not practiced as system-
atically as in our region prior to 1996.
This pre-symptomatic or early diagnosis of HH and fol-
low-up phlebotomy treatment should prove efficacious in
preventing organ damage and therefore aid in achieving
normal life expectancy for patients [48]. Early detection
can completely prevent premature death caused by HH.
Illustrating this point, Milman et al. found, through anal-
ysis of a cohort of patients diagnosed in Denmark
between 1945 and 1985, that the survival of HH patients
without cirrhosis or diabetes mellitus was similar to that
in the general population [48].
Conclusion
In conclusion, HFE mutation testing has supplemented
the determination of serum iron parameters as a criterion
for the diagnosis of HH. This has increased the proportion
of women diagnosed with HH and has decreased the fre-
quency of certain clinical signs at diagnosis. The method
of diagnosis of HH has changed and this has contributed
to modify the epidemiology of this disease, with the sex
ratio reduced to close to 1.0 and a weaker clinical expres-
sion than observed previously. This study highlights an
example of the progress enabled by Genomic Medicine
[49] and shows that knowledge of the molecular basis of
a disease (following identification of its gene and muta-
tions involved) can lead to a change in the epidemiology
of that disease.
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